NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Advanced or Metastatic Solid TumorsAdvanced or Metastatic Breast Cancer

Interventions

DRUG

Azacitidine (Vidaza)

50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle

DRUG

Nab-paclitaxel (Abraxane)

100mg/m2 weekly for 3 weeks of each 4-week cycle

Trial Locations (1)

University of Utah Huntsman Cancer Institute, Salt Lake City